Baseline laboratory values and metastatic burden predict survival in addition to IMDC risk in real-world renal cell carcinoma patients treated with ipilimumab-nivolumab
Baseline blood markers and number of metastatic sites add prognostic value independently of IMDC risk in real-word mRCC patients treated with ipililmumab-nivolumab.
Authors
- Magnus Lindskog (ORCID: https://orcid.org/0000-0001-9484-1983)
- Gustav Ullenhag (ORCID: https://orcid.org/0000-0003-4949-3267)
- Ingrida Verbiené
- A. Kheir
- Annika Håkansson
- Berglind Johannsdottir
- Fernanda Costa Svedman
- Rickard Carlhed
- Lisa L. Liu
- Anders Ullén (ORCID: https://orcid.org/0000-0002-9023-3259)
- Anna Laurell
- Ulrika Harmenberg
- Alexandra Grönn-Weiss
Institutions
- Uppsala University (SE)
- Karolinska University Hospital (SE)
- Uppsala University Hospital (SE)
- Science for Life Laboratory (SE)
- Karolinska Institutet (SE)
- Karlstad Central Hospital (SE)
Publication Details
- Journal
- Acta Oncologica
- Published
- 2025-10-03
- DOI
- https://doi.org/10.2340/1651-226x.2025.44533
- Citations
- 1
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- Cancerfonden
- Akademiska Sjukhuset
- Uppsala Universitet